Last updated: January 17, 2021
Sponsor: Sheba Medical Center
Overall Status: Active - Recruiting
Phase
2
Condition
Cataplexy
Cerebral Palsy
Treatment
N/AClinical Study ID
NCT04243408
SHEBA-18-5102-OBY-CTIL
Ages 2-12 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Age ≥ 2 month and ≤ 12 years.
- Performance status for children older than 2 months and younger than 12 monthsincluding all the following (Gross Motor Function Classification Score is lessindicative before 12 months):
- Abnormal General Movements (in infants 2-6 months)
- Abnormal Hammersmith Infant Neurological Examination
- Performance status for children older than 12 months
- Bilateral spastic cerebral palsy (diplegia or quadraplegia): Gross Motor FunctionClassification Score levels I - IV
- Spastic hemiplegia: Gross Motor Function Classification Score levels I - IV. Asubject classified as GMFCS level I with significant upper extremity impairmentwill be eligible if the affected upper extremity is used as an assist only.
- Bilateral hypotonic cerebral palsy (diplegia or quadraplegia): Gross MotorFunction Classification Score levels I - IV.
- An abnormal brain MRI suggestive of an acquired etiology (and not genetic etiology orbrain malformation).
- Autologous umbilical cord blood available at a private or public cord blood bankwith a minimum total nucleated cell dose of ≥ 2 x 10e7 cells/kilogram.
- Parental consent.
Exclusion
Exclusion Criteria:
- Autism and autistic spectrum disorders without motor disability.
- Hypsarrhythmia.
- Intractable seizures causing epileptic encephalopathy.
- Evidence of a progressive neurologic disease.
- Known HIV or uncontrolled bacterial, fungal, or viral infections.
- Impaired renal or liver function as determined by serum creatinine >1.5mg/dL and/ortotal bilirubin >1.3mg/dL.
- Head circumference >3 standard deviations below the mean for age.
- Known genetic disease or phenotypic evidence of a genetic disease on physicalexamination.
- Requires ventilatory support, including home ventilator
- Surgical procedure or botulinum toxin injection from 6 months prior to the study andduring the time of the study
- Patient's medical condition does not permit safe travel.
- Previously received any form of cellular therapy.
- Autologous umbilical cord blood unit has any of the following:
- Total nuclear cell dose < 2 x 10e7 cells/kilogram
- Positive maternal infectious disease markers (except CMV)
- Evidence of infectious contamination of the cord blood unit
- Lack of a test sample to confirm identity
- Evidence of a genetic disease
- Unable to obtain parental consent.
Study Design
Total Participants: 72
Study Start date:
July 08, 2020
Estimated Completion Date:
December 31, 2024
Connect with a study center
Chaim Seba Medical Center
Ramat Gan,
IsraelActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.